Guggenheim Reiterates Buy Rating on Veracyte, Inc. (VCYT)
Guggenheim maintains its buy rating on Veracyte with a $65 price target, a 10.68% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Veracyte, Inc. (VCYT) with a price target of $65 as of June 29, 2026.
- Guggenheim's $65 price target implies 10.68% upside from Veracyte, Inc.'s ($VCYT) current $58.73 share price.
- Shares of Veracyte traded near $60.49 on Monday, with a market cap of approximately $4.83 billion and a P/E ratio of 56.0.
- Other analysts, including Needham and UBS, have also maintained buy ratings, while Canaccord Genuity holds a neutral stance.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim has reiterated its buy rating on Veracyte, Inc. (NasdaqGM:VCYT), setting a price target of $65. This update, issued on June 29, 2026, reflects continued confidence in the company's prospects.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Veracyte, Inc., with a price target of $65. This aligns with recent analyst actions, as Needham also maintained a buy rating with a target of $57 on June 1, 2026. Canaccord Genuity, however, has held a more cautious stance, maintaining a hold rating with a $42 target as of May 6, 2026. UBS joined the optimistic outlook with a buy rating and a $52 target on the same date.
Veracyte, Inc. Stock Up 35.5%
Shares of Veracyte, Inc. traded near $60.49 on Monday. The company, with a market cap of approximately $4.83 billion, boasts a P/E ratio of 56.0 and a forward P/E of 31.8. Veracyte's stock has seen a 52-week low of $22.61 and a high of $60.83. The stock's 50-day moving average stands at $43.12, while the 200-day moving average is $39.05. The company maintains a robust liquidity position with a current ratio of 9.31 and a quick ratio of 8.72.
$VCYT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Veracyte reported revenue of $541.7 million, reflecting a growth rate of 21.5%. The company's net margin is 16.2%, with a return on equity of 6.9%. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Veracyte, Inc.
Recent insider activity at Veracyte included planned sales by Karin Eastham, who sold 3,729 shares at an average price of $52.89 on June 18, 2026. On June 11, 2026, multiple insiders, including Eliav Barr and Muna Bhanji, acquired 5,272 shares each, indicating confidence in the company's future.
About Veracyte, Inc.
Veracyte, Inc. is a healthcare company specializing in diagnostics and research, headquartered in South San Francisco, California. Led by CEO Marc A. Stapley, the company employs 755 people. Veracyte develops genomic tests that improve diagnostic accuracy for diseases such as thyroid and prostate cancer.
Bottom Line
Guggenheim's reiterated buy rating on Veracyte, Inc. underscores the firm's positive outlook for the company's future. As a diagnostics leader in the healthcare sector, Veracyte continues to attract attention from analysts and investors alike. This reiteration is based on past data and may not reflect current market conditions.
Get Veracyte, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VCYT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.